In theory, leaner NASA oversight, greater use of off‑the‑shelf hardware and narrower science goals can cut costs while ...

NASA’s ESCAPADE mission launched in 2025 to study Mars’ magnetic field and how solar wind has stripped away the planet’s atmosphere over time ...

Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.

Two years after Gilead Sciences secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to ...

A media marketing manager has settled her lawsuit against a former partner she accused of infecting her with an incurable and life-altering herpes virus after promising he was disease-free and failing ...

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...

Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

A media marketing manager has settled her lawsuit against a former partner she accused of infecting her with an incurable and ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...